Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer

To evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of the humanised antiepidermal growth factor receptor monoclonal antibody matuzumab combined with epirubicin, cisplatin and capecitabine (ECX) in patients as first-line treatment for advanced oesophagogastric cance...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Rao, S, Starling, N, Cunningham, D, Benson, M, Wotherspoon, A, Lüpfert, C, Kurek, R, Oates, J, Baselga, J, Hill, A
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2008
Assuntos:
Clinical Study
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2538760/
https://ncbi.nlm.nih.gov/pubmed/19238629
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6604622
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados